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Abstract
The toxicity of the five methylxanthine derivatives, caffeine, pentoxifylline, A802710, propentofylline and A802715, was
determined against the two human melanoma lines, Be11 and MeWo, and against the two human squamous cell carcinoma
lines, 4197 and 4451, by vital dye staining assay. Pentoxifylline and A802710 emerge as the least toxic showing TD50 (toxic
dose of 50%) levels of 3.0^4.0 mM. Propentofylline and caffeine take an intermediate position. A802715 has a TD50 of 0.9^
1.1 mM and is the most toxic. Subtoxic concentrations (6TD50) added after irradiation at maximum expression of the G2/M
block show that pentoxifylline and A802710 effectively abrogate the G2/M block, whereas A802715 and propentofylline
prolong the G2/M block or remain ineffective depending on the p53 status of the cell line. In p53 wt cells BrdU
incorporations show that the irradiation-induced suppression of S-phase entry is marginally enhanced by pentoxifylline but
strongly enhanced by propentofylline and A802715. This effect was not seen in p53 mutant cells. Since propentofylline and
A802715 prolong the G2/M block and effectively suppress BrdU incorporation these two drugs emerge as antagonists to
pentoxifylline, caffeine and A802710. Common structural features of propentofylline and A802715 are a propyl substituent
at the N7 position in contrast to pentoxifylline, caffeine and A802710 where the N7 substituent is a methyl group. The results
document the effectiveness of four methylxanthines in influencing cell regulation and damage response in human tumor
cells. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Subtoxic doses of pentoxifylline administered to
cells after irradiation at maximum expression of the
G2 block shortens the recovery period and cells re-
enter the cell cycle ahead of time [1^4]. This abrogat-
ing e¡ect initiated by pentoxifylline is not measurable
when the drug is added immediately before or after
irradiation, although improvements of the radiotox-
icity have been documented under these conditions
[5^8]. In p53 wild type (wt) cells where p53 and its
target genes are intact and active, irradiation induces
a G1 as well as a G2 block [5]. In p53 mutant cells
only a G2 block is induced. The application of pen-
toxifylline to irradiated p53 mutant and wt cells re-
sults in G2 blocked cells re-entering mitosis prema-
turely, before completing repair of the damaged
genome [7^12]. No measurable abrogating e¡ect of
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pentoxifylline is seen on the G1 cell cycle block in wt
cells. It is thought that this shortening of the G2
block eliminates a component of the cellular defence
and enhances the e¡ectiveness of genotoxic agents
[1,2,12^15]. The combination of G2 block abrogators
with cytostatic drugs indeed has lead to improve-
ments of cell kill and it is now generally agreed
that defective checkpoint controls and the absence
of a G1 block in p53 mutants is a situation which
may be exploited clinically [2,3,7,8,16,17]. It is not
resolved, however, whether cell cycle checkpoint de-
¢ciencies apparent in p53 mutant cells provide a de-
¢nitive advantage for therapeutic intervention. Many
checkpoint-activating agents like etoposide, cis-Pt or
irradiation are not uniformly successful in control-
ling p53 mutant tumors and it is accepted that check-
point de¢ciency alone cannot predict sensitivity to
genotoxins. In vitro experiments with p53 and p21
homozygous mutants, on the other hand, suggest
that a checkpoint-based strategy may be feasible
[18^22]. In this scenario it is clear that G2 block
abrogating drugs deserve attention. We have exam-
ined the methylxanthine derivatives pentoxifylline,
A802710, propentofylline and A802715 for their in-
£uence on G2 blocked cells, the G2 block recovery
time and entry into S-phase, using pentoxifylline as
standard. Experiments were performed on pairs of
human melanoma and squamous cell carcinoma
lines, where the Be11 and 4197 lines are p53 wt,
and the 4451 and MeWo lines carry a G to A muta-
tion in exon 7 codon 258, as described elsewhere [17].
Using a drug dose level below the TD50 (toxic dose
of 50%) accommodated toxicity di¡erences between
drugs and cell lines. The results serve to further eval-
uate the conditions required for targeted cell dereg-
ulation and the possibility of enhancing radiotoxicity
by cytotoxic drugs.
2. Materials and methods
The cell lines Be11 (p53 wildtype (wt)), MeWo
(p53 mutant) human melanoma cells, 4197 (p53
wt), and 4451 (p53 mutant) human squamous carci-
noma were kindly provided by F. Zoelzer and C.
Stre¡er, University of Essen. Cells were grown in
modi¢ed Eagle’s medium with 20% bovine calf serum
supplemented with 2 ml/l 1-glutamine, penicillin (100
Wg/ml) and streptomycin (100 Wg/ml) in 75 cm2 cell
culture £asks (Nunc) under standard conditions and
maintained at 37‡C with 5% CO2.
A802715 was kindly supplied by Professor M.
Scho«nharting (Hoechst Marion Roussell, HMR),
propentofylline and A802710 was provided by Dr.
K. Rudolphi (HMR) and pentoxifylline was obtained
from Noristan S.A.
2.1. Determination of the maximum expression of the
G2/M block
Irradiation was performed on asynchronous pop-
ulations of the cell lines with a dose of 7 Gy 60Co Q-
irradiation in 25 cm2 cell culture £asks. Cells were
incubated for 4^30 h and harvested according to Or-
merod [31] for £ow cytometric analysis in two-hourly
intervals by trypsinization, centrifugation and ¢xa-
tion in 70% ethanol for at least 30 min at 320‡C.
Assessment of the DNA was done by £ow cytomet-
ry. The cells were stained with 10 Wg/ml propidium
iodide solution (PI, Sigma) to which 100 Wg/ml
RNase (Boehringer Mannheim) was added. Samples
were incubated at 37‡C for 30 min and stored at 4‡C
under light protection.
2.1.1. S phase content
The staining of cells for £ow cytometric analysis of
DNA content and BrdU incorporation was as de-
scribed by Wilson [32]. Brie£y, at each time point,
cells in the exponential growth phase were pulse-la-
belled for 15 min at 37‡C with BrdU. Adding 100 Wl
of a 1 mM stock solution directly to 10 ml culture
medium gave a ¢nal BrdU concentration of 10 WM.
The BrdU-labelled cells ( þ 2U106 cells ¢xed in 70%
ethanol) were denaturated and nuclei released with
the HCl/pepsin method before antibody staining. For
immunochemical detection of BrdU the cells were
resuspended in 0.5 ml phosphate-bu¡ered saline
(PBS) containing 0.5% Tween 20, 0.5% normal
goat serum and 25 Wl mouse anti-BrdU (Dako,
M0744). The second step included a cell resuspension
in 0.5 ml of PBS containing 0.5% Tween 20, 0.5%
normal goat serum and 25 Wl anti-mouse FITC-con-
jugated antibody (Sigma, F-2012). Nuclei collected
by centrifugation were counterstained with 10 Wg/
ml PI at room temperature. Flow cytometric analysis
was performed within 3 h after completion of stain-
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ing. The % S-phase was measured in a dot plot of
FL-2 (red £uorescence or total DNA content by a
600 nm bandpass ¢lter) against FL-1 (green £uores-
cence or BrdU content by a 544 nm bandpass ¢lter).
The BrdU positive part of this plot was used to cal-
culate % S-phase cells sampled at di¡erent time
points. All measurements were repeated three times.
2.1.2. Determination of DNA content by £ow
cytometry
DNA analysis was performed using a FACScan
£ow cytometer (Becton Dickinson) emitting a 488
nm beam. Red £uorescence from PI emission was
collected as a linear signal through a 600 nm band-
pass ¢lter and recorded as a measure of total DNA
content. Processing the red £uorescence into height,
area and width (doublet discrimination mode) elimi-
nated cell doublets. Data were collected in list mode
and 10 000 events were recorded per sample and dis-
played as a frequency distribution histogram. Esti-
mates of the percentages of cells in the di¡erent pe-
riods of postirradiation incubation with marker
statistics (LYSIS II software; Becton Dickinson) re-
vealed the time at which the G2/M block was max-
imally expressed. These times were used for each cell
line as a starting point at which the methylxanthine
drugs were added. Cell debris, nuclei doublets and
triplets were excluded by gating.
2.2. Induction of mitotic block with nocodazole
Nocodazole was dissolved in warm sterile DMSO
at a concentration of 1 mg/ml and diluted in DMSO
to a stock concentration of 0.1 mg/ml. The working
concentration in the culture medium was 0.4 Wg/ml.
Pentoxifylline was added after 14^16 h when the
nocodazole-induced M block had reached a maxi-
mum.
2.3. Toxicity studies
The cytotoxicity of the drugs was measured using
the crystal violet assay. Cells were seeded at a density
of 5000^10 000 cells/well in a 24-well multiplate and
grown for 24 h. Cells were cultivated with the drug
for 24 h. Four days after change of medium the cells
were ¢xed in bu¡ered formalin (pH 7.2), washed,
viable cells stained with crystal violet, and the ex-
tracted dye read spectrophotometrically at 590 nm
as described [38]. The drug concentration at which
the cell survival was reduced to 50% (TD50) was then
determined. All measurements were done in triplicate
and each experiment was repeated three times.
3. Results
The drugs employed in these studies were ca¡eine
(1,3,7 trimethylxanthine), pentoxifylline (1-(5-oxo-
hexyl)-3,7-dimethylxanthine), A802710 (1-(5-hydroxy-
hexyl)-3,7-dimethylxanthine),propentofylline(3-meth-
yl-1-(5-oxohexyl)-7-propylxanthine) and A802715
(3-methyl-1-(5 hydroxy, 5 methylhexyl)-7-propyl-
xanthine) (Fig. 1).
Toxicity studies using four representative human
tumor cell lines showed that A802715 has a TD50
of 0.9^1.1 mM and is by far the most toxic drug.
Pentoxifylline and A802710 have a TD50 of 3.0^6.0
mM and emerge as the least toxic. Propentofylline
and ca¡eine take intermediate positions with TD50’s
of 1.3^2.0 and 2.2^4.0 mM, respectively (Table 1).
The e¡ectiveness of the drugs as growth inhibitors
was established by the crystal violet vital dye-staining
assay (see Section 2) and served to establish the con-
centration levels at which the drug was beginning to
show a growth inhibiting e¡ect. These concentrations
(2 mM for pentoxifylline and A802710, and 1 mM
for propentofylline and A802715) were then used to
Table 1
In£uence of methylxanthine drugs on cell viability as measured by TD50 dose (mM) using crystal violet dye staining assay
Cell line A802715 Propentofylline Ca¡eine Pentoxifylline A802710
MeWo 1.06 1.3 2.24 3.17 4.3
Be11 0.86 2.0 2.42 6.0 6.0
4451 1.1 2.0 3.22 4.1 3.3
4197 1.07 1.7 3.92 5.6 4.2
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test the e⁄cacy of four methylxanthine derivatives in
abrogating cell cycle blocks induced by irradiation.
3.1. Drug e¡ects
The e¡ect of irradiation on p53 wt cells is a mar-
ginal decline and then blockage of the G1 population
and an increase of the G2 population, and this is
associated with a decline of BrdU incorporation,
arising from the inhibition of S-phase entry by p21.
The initial decrease observed in G1 during block
formation can be attributed to an overlap of cell
populations in the £ow histogram. In 4197 cells, ad-
dition of the drugs close to the estimated maximum
expression of the G2 block shows that pentoxifylline
and A802710 e¡ectively reduce the G2 population
below control level, whereas propentofylline and
A802715 elevate the G2 population (Fig. 2A). In
the Be11 melanoma cell line, propentofylline and
A802715 remain ine¡ective in in£uencing the G2
population, whereas pentoxifylline and A802710
clearly suppress the G2 population (Fig. 2B). Pent-
oxifylline and A802710 have no pronounced e¡ect on
S-phase contents (Fig. 3A,B) which con¢rms that the
G2 block, but not the G1 block, is abrogated in wt
cells. The in£uence of the other drugs on BrdU in-
corporation is noticeable in the case of propentofyl-
line and A802715 which strongly enhance the irradi-
ation-induced suppression of S-phase contents (Fig.
3A,B) and this e¡ect is more strongly expressed with
A802715.
Fig. 2. In£uence of methylxanthine derivatives on the irradia-
tion-induced G2/M block in p53 wt 4197 (A) and Be11 (B) cell
lines, and in p53 mutant MeWo (C) and 4451 (D) cell lines.
The arrow indicates addition of the drug, which was close to
the maximum expression of the cell cycle block. Error bars rep-
resent 1 S.D. 8, irradiation only; F, irradiation+2 mM pentox-
ifylline; R, irradiation+1 mM propentofylline; a, irradiation+1
mM A802715; *, irradiation+2 mM A802710
Fig. 1. Methylxanthine derivatives examined were ca¡eine and
the four Hoechst drugs, pentoxifylline, propentofylline,
A802715 and A802710.
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In p53 mutant cells, irradiation induces a strong
decline of the G1 population and elevation of the G2
population giving rise to a G2 block (Fig. 2C,D).
The G2 block is associated with a strong increase
of BrdU incorporation in MeWo cells, which show
an increase in the S-phase content from 20 to 47%
(Fig. 3C). This may be due to a block in G2, while
the progression of cells from G1 into S-phase con-
tinues normally. Interestingly, a similar phenomenon
is not observed in the 4451 p53 mutant cell line (Fig.
3D). In p53 mutant cells, the increase of the G2
population after irradiation is e¡ectively reversed
by pentoxifylline and A802710 (Fig. 2C,D) but not
by propentofylline and by A802715 (Fig. 2C,D). This
shows that pentoxifylline and A802710 are e¡ective
G2 block abrogators. The e¡ect of A802710 and
pentoxifylline on irradiated p53 mutant cells was
also monitored in the G1 population, which rapidly
responds to the stimulation of mitosis and re-entry
into the cell cycle. Addition of pentoxifylline at max-
imum expression of the G2 block sharply increases
the percentage of G1 cells and produces a character-
istic overshoot of the G1 population above the level
of non-irradiated controls (G1 data not shown). In
p53 mutant cells, which exhibit no G1 cell cycle
block, the methylxanthine drugs do not in£uence S-
phase as measured by BrdU incorporation (Fig.
3C,D).
When G2 blocks were induced with the spindle
inhibitor nocodazole instead of irradiation, the block
was unresponsive to pentoxifylline in p53 wt (Fig.
4A,B) and p53 mutant cells (Fig. 4C,D). A 7 h ex-
posure to pentoxifylline completely abrogates the ir-
radiation-induced G2 block (Fig. 5A,B), whereas a
6 h exposure to pentoxifylline in nocodazole-treated
cells remains essentially ine¡ective in reducing the G2
population (Fig. 4B,D). In the nocodazole experi-
ments, exposure to pentoxifylline for up to 10 h
was found to be ine¡ective and G2 populations re-
mained at the level of 40% in p53 wt cells and at 80%
in p53 mutant cells. This shows that pentoxifylline
does not reverse the inhibition of spindle assembly
and operates at another level.
4. Discussion
4.1. Pentoxifylline and A802710
The cytotoxicity of methylxanthine derivatives
varies between cell lines. Pentoxifylline and
A802710 emerge as the least toxic whereas A802715
and propentofylline are distinctly more toxic. The
lower toxicity of pentoxifylline and A802710 renders
these drugs more attractive for clinical application
than ca¡eine [3,23]. The e¡ectiveness of pentoxifyl-
line in abrogating the G2 block in p53 mutant cells
has been analyzed [1^3,5^8]. Early resumption of the
cell cycle progression after DNA damage clearly is
an attractive avenue for further intervention with
cytotoxic drugs [24].
Fig. 3. In£uence of methylxanthine derivatives on DNA synthe-
sis in p53 wt 4197 (A) and Be11 (B) cell lines, and in p53 mu-
tant MeWo (C) and 4451 (D) cell lines. Arrow indicates addi-
tion of the drug, which was close to the maximum expression
of the cell cycle block. S-phases were quantitated by double pa-
rameter analysis of total DNA content (red £uorescence) and
incorporated BrdU (green £uorescence) using PI and anti-BrdU
antibodies labelled with FITC. Error bars represent 1 S.D. 8,
irradiation only; F, irradiation+2 mM pentoxifylline; R, irradi-
ation+1 mM propentofylline; a, irradiation+1 mM A802715;
*, irradiation+2 mM A802710
BBAMCR 14660 6-12-00
L. Bohm et al. / Biochimica et Biophysica Acta 1499 (2000) 1^10 5
4.2. Propentofylline and A802715
These two xanthine derivatives di¡er markedly
from pentoxifylline and A802710 in that they do
not inhibit the G2/M block. The G2 versus time
relationship for these two drugs is very similar in
all four cell lines. A close functional resemblance is
particularly apparent in 4197 p53 wt cells where
these two drugs prolong the G2/M population by a
Fig. 4. In£uence of pentoxifylline on nocodazole-induced mitotic blocks in p53 wt 4197 cells (A and B) and p53 mutant 4451 cells (C
and D). Nocodazole was added to the culture medium at 0.4 Wg/ml. When the mitotic block had reached a maximum at 14^16 h in
4197 and 4451 (A and C) cells, 2 mM pentoxifylline was added. Presence of pentoxifylline for 6^10 h did not abrogate the nocoda-
zole-induced mitotic block and the G2/M population remained essentially unchanged (B and D).
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similar margin, whereas pentoxifylline A802710 sup-
presses it (Fig. 2A).
Inspection of S-phase contents in the two p53 wt
cells show that propentofylline and A802715 enhance
the suppression of BrdU incorporation induced by
irradiation (Fig. 3A,B). In the MeWo p53 mutant
cell line the S-phase content is elevated after irradi-
ation (Fig. 3C). This is interpreted as an inhibition of
S-phase progression [14,25] which is cell type speci¢c,
as it is not observed in the 4451 p53 mutant cell line.
The continuation of replication in the absence of
mitosis (endoreplication) is known to give rise to
higher ploidy and such e¡ects were indeed observed
in the MeWo cells (data not shown). A802715 and
propentofylline suppress entry of irradiated cells into
S-phase in p53 wt cells, which can be attributed to an
active G1 cell cycle block (Fig. 3A,B). Since all drugs
were employed at or near the TD50 these results
could not arise from toxicity di¡erences or simply
from cell kill. The e¡ectiveness of propentofylline
Fig. 5. DNA histograms and dot plots from BrdU incorporation in 4197 p53 wt and 4451 p53 mutant cells in response to cobalt Q-ir-
radiation and addition of pentoxifylline at the G2/M maximum.
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and A802715 in suppressing the entry of cells into S-
phase sharply contrasts with pentoxifylline, which
has little or no e¡ect on S-phase entry (Fig. 3A,B).
Due to the lack of a functional G1 checkpoint, the
four drugs have little or no e¡ect on S-phase popu-
lations in the two p53 mutant cell lines (Fig. 3C,D).
Propentofylline and A802715 prolong the G2 block
induced by irradiation, or leave it una¡ected, and
thus emerge as antagonists to ca¡eine, pentoxifylline
and A802710. Propentofylline and A802715 have
been found to exhibit a very strong capacity to sup-
press tumor necrosis factor K (TNF-K) and inhibit
3P,5P-c-AMP phosphodiesterase (PDE) activity.
A802715 has been found to be the most potent
TNF-K inhibitor and this inhibitory capacity corre-
lates with the PDE inhibition of the xanthine drug
[26,27]. Other studies indicated that A802715 is much
more potent than pentoxifylline in the mixed lym-
phocyte reaction and hence emerge as a strong im-
mune-suppressant [28]. Propentofylline has been
shown to inhibit adenosine transport into cells and
increases extra-cellular adenosine concentrations
thereby simulating adenosine receptors and exhibit-
ing a neuroprotective e¡ect far in excess of pentoxi-
fylline [29].
The remarkable functional similarity between pro-
pentofylline and A802715 raises the question of
structural interrelationships. Ca¡eine, pentoxifylline
and A802710 carry a methyl substituent at N7
(Fig. 1) whereas propentofylline and A802715 carry
a propyl residue at N7. Since G2 block inhibition is
shown by ca¡eine [8,30,33^37], pentoxifylline and
A802710, which are N7-methyl, it appears that the
e¡ectiveness of these three drugs as G2/M block ab-
rogators may lie in the N7 substituent. Variations in
N1 substituent (methyl for ca¡eine, 5-oxohexyl for
pentoxifylline and 5-hydroxyhexyl for A802710) are
of little consequence for the G2 block abrogator ac-
tivity, but replacement of the N7 methyl group by a
propyl group in A802715 and in propentofylline
abolishes the G2 block inhibition activity. This sug-
gests that the activity of methylxanthines in cell reg-
ulation may indeed rest in the N7 substituent. The
use of other model compounds would help to cor-
roborate this impression.
Methylxanthines are potent PDE inhibitors
[38,39]. It is also well known that the association of
cyclin B1 and cyclin-dependent kinases into the ac-
tive cyclin B1/p34cdc2 complex is regulated by activat-
ing phosphatases [40]. The possibility, therefore, ex-
ists that pentoxifylline inhibits this activation step.
Alternatively, the drug could in£uence the cyclin
B1 constituent. The use of anti-cyclin B1 antibodies
indeed have shown that irradiation decreases cyclin
B1 expression and that pentoxifylline restores the
cyclin B1/G2 ratio to control levels [41]. Elevation
of cyclin B1 expression, therefore, must be consid-
ered as part of the mechanism of action of pentoxi-
fylline as a G2 block abrogator. The fact that pent-
oxifylline does not abrogate G2 blocks induced by
the microtubule inhibitor nocodazole (Fig. 4), sug-
gests that pentoxifylline does not operate at the spin-
dle assembly checkpoint.
Our studies on the in£uence of methylxanthine
derivatives on cell regulation demonstrate that only
the two N-7 methyl derivatives e¡ectively abrogate
the damage-induced G2 cell cycle block, whereas the
two N-7 propyl derivatives are ine¡ective. The e¡ec-
tiveness of N-7 methyl in G2 block abrogation also
applies to ca¡eine [41]. The N-7 propyl derivatives
also di¡er from the N-7 methyl derivatives in that
they enhance the suppression of the S-phase after
irradiation in p53 wt cells, but show no e¡ect on
the S-phase in irradiated p53 mutant cells. The func-
tional distinction of the two groups of drugs in terms
of cell regulation suggests a di¡erential in£uence on
cyclin-dependent kinases and a mechanism involving
the activation and intracellular location of the cyclin
B1/p34cdc2 complex has been considered [42^44].
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